Status:
TERMINATED
Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Chronic Renal Failure
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Diabetes kidney disease is a leading cause for end stage renal disease in the western world. To date no treatment that can reverse renal damage exists. Chronic hypoxia is one of the major key insults...
Detailed Description
Scientific background Diabetic Kidney Disease (DKD): The kidneys, which are an important target for diabetic induced damage, contribute a lot to this burden. Diabetic nephropathy (DN) is the most co...
Eligibility Criteria
Inclusion
- The participants are patients of age 18 years or older, who suffered DKD, defined as eGFR\<60ml/min as estimated using MDRD formula, and albuminuria in the presence of diabetes. Diabetic retinopathy and without any alternative cause for their renal disease.
Exclusion
- Exclusions criteria are chest pathology incompatible with HBOT, inner ear disease, claustrophobia. Smoking is not allowed during the study. Patients with uncontrolled diabetes HBA1C\>7.5, recent AKI (3M) recent cardiovascular or cerebrovascular event (6M) or inability to hold the breath for 20-30 seconds are also excluded.
Key Trial Info
Start Date :
September 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 4 2020
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03376282
Start Date
September 1 2015
End Date
May 4 2020
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dialysis Clinic in Asaf Harofhe Medical Center
Ẕerifin, Israel, 70300